bioRxivImmunology
SARS-CoV-2 Vaccines Elicit Durable Immune Responses in Infant Rhesus Macaques
C. G. Garrado, A. D. Curtis, M. Dennis, S. H. Pathak, H. Gao, D. Montefiori, M. Tomai, C. B. Fox, P. A. Kozlowski, T. Scobey, J. E. Munt, M. L. Mallory, P. T. Saha, M. G. Hudgens, L. C. Lindesmith, R. S. Baric, O. M. Abiona, K. S. Corbett, D. Edwards, A. Carfi, G. Fouda, K. K. A. Van Rompay, K. De Paris, S. R. Permar
Abstract
Early life SARS-CoV-2 vaccination has the potential to provide lifelong protection and achieve herd immunity. To evaluate SARS-CoV-2 infant vaccination, we immunized two groups of 8 infant rhesus macaques (RMs) at weeks 0 and 4 with stabilized prefusion SARS-CoV-2 S-2P spike (S) protein, either encoded by mRNA encapsulated in lipid nanoparticles (mRNA-LNP) or mixed with 3M-052-SE, a TLR7/8 agonist in a squalene emulsion (Protein+3M-052-SE). Neither vaccine induced adverse effects. High magnitude S-binding IgG and neutralizing infectious dose 50 (ID50) >103 were elicited by both vaccines. S-specific T cell responses were dominated by IL-17, IFN-{gamma}, or TNF-. Antibody and cellular responses were stable through week 22. The S-2P mRNA-LNP and Protein-3M-052-SE vaccines are promising pediatric SARS-CoV-2 vaccine candidates to achieve durable protective immunity. One-Sentence SummarySARS-CoV-2 vaccines are well-tolerated and highly immunogenic in infant rhesus macaques
- organism: rat
- assay: proteomics
- assay: flow cytometry
- research focus: host-pathogen & immune response
- research focus: cell type annotation
- research focus: differential expression
- approach: experimental assay
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- SARS-CoV-2 binding and neutralizing antibody levels after vaccination with Ad26.COV2.S predict durable protection in rhesus macaques
R. Roozendaal, L. Solforosi, … R. Zahn·bioRxiv·Jan 30, 2021
- Intranasal pediatric parainfluenza virus-vectored SARS-CoV-2 vaccine candidate is protective in macaques
C. Le Nouen, C. E. Nelson, … U. J. Buchholz·bioRxiv·May 21, 2022
- Two-component spike nanoparticle vaccine protects macaques from SARS-CoV-2 infection
P. J. M. Brouwer, M. Brinkkemper, … de Bree·bioRxiv·Nov 7, 2020
- Protein Vaccine Induces a Durable, More Broadly Neutralizing Antibody Response in Macaques than Natural Infection with SARS-CoV-2 P.1
A. To, T. A. S. Wong, … A. T. Lehrer·ACS Infectious DiseasesPeer-reviewed·Mar 9, 2022
- A valid protective immune response elicited in rhesus macaques by an inactivated vaccine is capable of defending against SARS-CoV-2 infection
- Evaluation of mRNA-LNP and adjuvanted protein SARS-CoV-2 vaccines in a maternal antibody mouse model
R. N. England, E. M. Drapeau, … S. E. Hensley·bioRxiv·Apr 12, 2023